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Background: The lack of uniform criteria for coding of gastroenteropancreatic neuroendocrine
neoplasia (GEP-NEN) has hampered previous epidemiological studies. The epidemiology of GEP-NEN
was investigated in this study using currently available criteria.
Methods: All patients diagnosed with GEP-NEN between January 2003 and December 2013 in a well
defined Norwegian population of approximately 350 000 people were included. Age- and sex-adjusted
incidence rates were calculated. The current 2010World Health Organization criteria, European Neuro-
endocrine Tumour Society classification and International Union Against Cancer (UICC) classification
were used.
Results: A total of 204 patients (114 male, 55⋅9 per cent) were identified. The median age at diagnosis
was 61 (range 10–94) years. The annual overall crude incidence was 5⋅83 per 100 000 inhabitants, with
an increasing trend (P = 0⋅033). The most frequent location was small intestine (60 patients, 29⋅4 per
cent) followed by appendix (48 patients, 23⋅5 per cent) and pancreas (33 patients, 16⋅2 per cent). Grade
1 tumours were more common in gastrointestinal (100 patients, 58⋅5 per cent) than in pancreatic (9
patients, 27 per cent) NEN. According to the UICC classification, 77 patients (37⋅7 per cent) had stage I,
17 patients (8⋅3 per cent) stage II, 37 patients (18⋅1 per cent) stage III and 70 patients (34⋅3 per cent) had
stage IV disease. No patient with stage I disease had grade 3 tumours; advanced tumour grade increased
with stage.
Conclusion: A high crude incidence of GEP-NEN, at 5⋅83 per 100 000 inhabitants, was noted together
with a significant increasing trend over time.
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Introduction
Gastroenteropancreatic neuroendocrine neoplasia (GEP-
NEN) originates from the diffuse neuroendocrine cell
system of the gastrointestinal tract and pancreas, and
represents 1–1⋅5 per cent of all GEP neoplasms1,2. This
heterogeneous group of epithelial neoplasms is highly
variable in its clinical presentation, malignant potential and
prognosis3.
In 1867, the neuroendocrine tumour (NET) was first
described as a specific entity4. A system for tumour classi-
fication was initially developed5, but the nomenclature for
this entity has been inconsistent. Numerous classification
systems for staging and grading based on embryology,
morphology or biochemistry have been proposed, with
none gaining robust acceptance over time5–7.
The current 2010 World Health Organization (WHO)
classification of GEP-NEN is based on histological grade
and derived from degree of differentiation and the Ki-67
index, as proposed by the European Neuroendocrine
Tumour Society (ENETS) in 2006 and 20078–10. Other
characteristics, including tumour size and location and
presence of metastases, are incorporated into the ENETS
2006–2007 TNM system8,9. In 2009, the International
Union Against Cancer (UICC) published another TNM
system for tumour staging11. By the introduction of
a uniform nomenclature and classification system for
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GEP-NEN, improved and comparable epidemiological
data should eventually be available. In the past the epidemi-
ology of GEP-NEN has been examined based on regional
and national registries in Europe, the USA and Asia12–26.
To circumvent many of the shortcomings of previous
studies regarding definitions and reporting, this cohort
study evaluated the epidemiological characteristics of
patients diagnosed with GEP-NEN based on the most
recent WHO and ENETS/UICC classifications, using a
population-based, single-institution, consecutive series of
patients treated over a decade.
Methods
This manuscript was completed in accordance with the
Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement27. The Hospital
Review Board approved the study (2011/1659-16) accord-
ing to the general guidelines provided by the Regional
Ethics Committee.
Population sample
Stavanger University Hospital, as the only hospital in the
region, serves a catchment area of 18 municipalities in
south-western Norway. It provides healthcare services to
a well defined population that has increased from approx-
imately 290 000 inhabitants in 2003 to more than 350 000
in 201428. The study included all patients initially diag-
nosed with GEP-NEN in this region during the 11-year
interval from 1 January 2003 to 31 December 2013. All
permanent residents of Norway are assigned an 11-digit
identification number in the National Population Registry.
Any change of address must be reported to the National
Population Registry within 8 days of moving. The hospi-
tal’s patient administrative system is linked electronically
to the National Population Registry28, enabling continued
contact for follow-up assessments.
Identification of patients
Eligible patients were identified through a review of
all NEN diagnoses recorded in the hospital’s elec-
tronic pathology files. The data files were searched
for histopathological or cytological diagnoses according to
the Systematized Nomenclature of Medicine (SNOMED)
classification system (Norwegian version) (topography
T56/59/62-68; diagnosis M80411-3+6/M82401-6/
M82431-3/M82441-3/M82451/M82461-3+6). Neuro-
endocrine neoplasms of the gastrointestinal tract and
pancreas were identified. Lesions with histomorphology
and immunohistochemistry (IHC) profiles consistent
with GEP-NEN were included. Where necessary, his-
tology was re-evaluated, particularly with regard to the
completeness of the IHC data (chromogranin A, synapto-
physin, Ki-67, thyroid transcription factor 1 and CDX2,
among others) and the proportion of different histological
components in mixed adenoneuroendocrine carcinoma
(MANEC).
Neuroendocrine liver tumours (labelled unknown)
were included when an extrahepatic tumour outside the
abdomen could be excluded via imaging or when the IHC
profile did not suggest a primary lung tumour. All patients
who underwent somatostatin receptor scintigraphy at the
hospital during the study were reviewed to identify eligible
patients with NEN not confirmed by histology. A search
for eligible patients from the Stavanger University Hospi-
tal catchment area was also undertaken at a collaborating
institution (Haukeland University Hospital, Bergen).
Patients diagnosed with primary non-gastrointestinal
NEN, including lung, Merkel cell carcinomas, prostate,
urinary bladder, uterus, breast, head and neck or otherwise
misclassified tumours (by either location or histopathol-
ogy), were excluded from the analysis.
Patient demographics and clinical information, includ-
ing date of diagnosis, location of tumours and presence
of regional and/or distant metastases, were retrieved
from hospital records, autopsy reports, and information
from general practitioners and the National Population
Registry28. The tumour characteristics recorded were: size,
mitotic count (per high-power field) and the expression of
Ki-67 (in ‘hot spots’), synaptophysin and chromogranin A
by IHC.
Definitions
The patients were grouped according to the 2010 WHO
classification29 (Table 1), and staged according to the
2006–2007 ENETS8,9 and 2009 UICC11 criteria for
TNM classification, for comprehensive and compara-
ble reporting. In MANEC, both the high-grade neuro-
endocrine and the adenocarcinoma proportion exceed 30
per cent.
Annual age- and sex-adjusted incidence rates were calcu-
lated by direct standardization with 5-year intervals for age
(with an open-ended interval from 85 years or more) using
the World30, USA 200031, WHO32 and European 201333
standard populations, along with the Norwegian popula-
tion (for each year) retrieved from Statistics Norway28,
as references. The population size for each year was the
calculated average of the population at the beginning and
end of the year.
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Table 1 2010 World Health Organization classification of
gastroenteropancreatic neoplasia
Mitoses
(per 10 HPFs)
Ki-67
index
Neuroendocrine tumour
Grade 1 (carcinoid) <2 ≤2
Grade 2 2–20 3–20
Neuroendocrine carcinoma
Grade 3 – large cell or small cell type >20 >20
Mixed adenoneuroendocrine carcinoma
Hyperplastic and preneoplastic lesions
At least 50 high-power fields (HPFs) counted (2mm2, original
magnification ×40). Ki-67 immunoreactivity evaluated in ‘hot spots’.
Statistical analysis
SPSS® version 22.0.0.0 for Mac (IBM, Armonk, New
York, USA) and R3.1.0 (R Foundation for Statistical
Computing, Vienna, Austria) were used for data analysis.
Non-parametric tests were used for comparisons between
subgroups, and log-linear Poisson regression analysis
to test for differences in crude incidence over the study
interval. To calculate age- and sex-adjusted incidence,
the epitools package in R 3.1.0 was used34. All tests were
two-sided, and P < 0⋅050 was considered significant.
Results
A total of 204 patients with GEP-NEN were identified,
including 198 (97⋅1 per cent) with a confirmed histopatho-
logical diagnosis. Six patients (2⋅9 per cent) were included
based on convincing clinical findings: a raised level of
serum choromgranin A and positive imaging findings (CT
and somatostatin receptor scintigraphy). The search at
Haukeland University Hospital identified three patients.
A male predominance was observed (114 patients, 55⋅9
per cent; P= 0⋅017). Patient demographics are summarized
in Table 2. Age at diagnosis did not differ between men
and women (median age 61⋅5 and 60⋅5 years respectively;
P = 0⋅344).
Patients with NEN of the appendix were significantly
younger than those with tumours at other sites (median age
30 years for appendix versus 64 years for other locations;P <
0⋅001). In addition, patients withWHO grade (G) 1 NETs
were significantly younger than those with G2 NETs and
G3 neuroendocrine carcinomas (NECs) (median age 55⋅1
versus 65⋅3 and 66⋅2 years respectively; P < 0⋅001).
Incidence by sex and time
The annual overall crude incidence was 5⋅83 per 100 000
inhabitants (6⋅47 and 5⋅19 per 100 000 for men and women
respectively). Standardized directly to the Norwegian
population, the annual incidence rate was 6⋅62 per 100 000
inhabitants, with rates of 7⋅41 and 5⋅83 per 100 000 for
men and women respectively.
The annual adjusted incidence rates standardized for
different populations are shown in Table 3. Regardless of
the standard population employed, the incidence remained
high, and varied between a low annual crude incidence of
2⋅37 per 100 000 in 2004 to the highest incidence of 8⋅35
per 100 000 in 2009 (Fig. 1), with an increasing trend during
the study period (P = 0⋅033).
Men were more frequently diagnosed with small intesti-
nal (P < 0⋅001) and duodenal (P = 0⋅011) NEN, whereas
tumours of unknown origin were more frequently found in
women (P = 0⋅004) (Table 2).
Incidence by location
Almost one-third of the primary tumours (60, 29⋅4 per
cent) were located in the small intestine (excluding the duo-
denum but including 2 NETs in Meckel’s diverticulum),
and the appendix was the second most common tumour
Table 2 Clinical characteristics according to tumour location
Sex Median (years)* Crude incidence (per 100 000)
Overall Male Female All Male Female All Male Female
All 204 (100) 114 (55⋅9) 90 (44⋅1) 61 (10–94) 61⋅5 (13–94) 60⋅5 (10–88) 5⋅83 6⋅47 5⋅19
Oesophagus 3 (1⋅5) 1 (33) 2 (67) 76 (69–83) 76 76 0⋅09 0⋅06 0⋅12
Stomach 11 (5⋅4) 8 (73) 3 (27) 66 (35–94) 64 69 0⋅31 0⋅45 0⋅17
Duodenum 5 (2⋅5) 5 (100) 0 (0) 68 (47–76) 68 – 0⋅14 0⋅28 –
Small intestine 60 (29⋅4) 40 (67) 20 (33) 64 (48–91) 63 72 1⋅72 2⋅27 1⋅15
Appendix 48 (23⋅5) 22 (46) 26 (54) 30 (10–85) 33 29 1⋅37 1⋅25 1⋅50
Colon 15 (7⋅4) 9 (60) 6 (40) 62 (42–84) 59 71 0⋅46 0⋅51 0⋅35
Rectum 18 (8⋅8) 8 (44) 10 (56) 58 (37–84) 48 61 0⋅51 0⋅45 0⋅58
Pancreas 33 (16⋅2) 20 (61) 13 (39) 61 (20–85) 60 61 0⋅94 1⋅13 0⋅75
Bile duct 2 (1⋅0) 0 (0) 2 (100) 51 (23–80) – 51 0⋅06 – 0⋅12
Unknown 9 (4⋅4) 1 (11) 8 (89) 78 (48–87) 63 80 0⋅26 0⋅06 0⋅46
Values in parentheses are percentages unless indicated otherwise; *values are median (range).
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Table 3 Incidence rates of gastroenteropancreatic neoplasia, with adjusted rates related to common reference populations
Incidence (per 100 000 per year)
Crude Norway World WHO USA 2000 Europe 2013
All 5⋅83 6⋅62 4⋅43 4⋅86 5⋅68 7⋅64
Male 6⋅47 7⋅41 4⋅83 5⋅40 6⋅15 9⋅08
Female 5⋅19 5⋅83 4⋅02 4⋅31 5⋅23 6⋅20
WHO, World Health Organization.
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Fig. 1 Annual incidence per 100 000 by year in the study period.
Poisson regression analysis shows a statistically significant
increase in the annual crude incidence (P = 0⋅033)
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Fig. 2 World Health Organization tumour grade by organ. Of
note is the wide variation in tumour grade between locations;
low-grade tumours are most commonly encountered in the
duodenum, small intestine and appendix
site (48, 23⋅5 per cent) (Table 2). A sixth of the tumours (33,
16⋅2 per cent) originated in the pancreas, including three
tumours in patients with multiple endocrine neoplasia type
1 syndrome (MEN-1).
Multiplicity, defined as primary NEN in two different
organs, was found in three patients: in the duodenum and
stomach in one patient, the small intestine and appendix in
another, and the pancreas and duodenum in a third patient
with MEN-1. Multifocal tumours in the small intestine
were encountered in 21 (35 per cent) of 60 patients.
Tumour grade and stage at diagnosis
A total of 109 patients (53⋅4 per cent) had G1 NETs,
49 (24⋅0 per cent) had G2 NETs, and 40 (19⋅6 per
cent) patients were diagnosed with G3 NEC. Male and
female patients were distributed similarly across grades.
The annual incidence rates for G1 tumours were 3⋅51 and
2⋅71 per 100 000 males and females respectively. For G2
tumours, respective rates for males and females were 1⋅53
and 1⋅27 per 100 000, and for G3 they were 1⋅30 and 0⋅98
per 100 000. Grade distribution for different locations is
shown in Fig. 2. Grade 1 tumours were more common in
gastrointestinal (100 patients, 58⋅5 per cent) than in pan-
creatic (nine patients, 27 per cent) NEN. All duodenal and
appendiceal tumours, and most small intestinal (57 of 60),
pancreatic (23 of 33) and rectal (12 of 18) tumours, showed
G1/G2 differentiation. All three oesophageal NETs, a
majority of the colonic NETs (11 of 15) and six of nine
NETs with an unknown primary tumour site showed G3
differentiation. Four of the G3 NECs were classified as
MANECs. Two appendiceal tumours were diagnosed as
goblet cell carcinoids, which are currently regarded as a
specific entity35,36. This entity should no longer be classi-
fied as a NEN (ENETS, personal communication, 2015).
Half of patients (98, 48⋅0 per cent) had regional lymph
node metastases, and more than one-third (70, 34⋅3 per
cent) had distant organ metastases (liver, lung and distant
lymph nodes) at the time of diagnosis. Ten of 15 patients
with colonicNENpresentedwith distant organmetastases,
whereas only one of the 48 patients with a primary appen-
diceal NEN had distant metastases. Regional lymph node
involvement was present in most patients with NEN in the
small intestine (52 of 60) and colon (12 of 15).
According to the UICC classification, 77 patients (37⋅7
per cent) had stage I, 17 patients (8⋅3 per cent) stage
II, 37 patients (18⋅1 per cent) stage III and 70 patients
(34⋅3 per cent) had stage IV disease. No patient with
stage I disease had grade 3 tumours; advanced tumour
grade increased with stage. The distribution of tumour
© 2015 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Fig. 3 Distribution by tumour location according to stage at the
time of diagnosis. *European Neuroendocrine Tumour Society
(ENETS) criteria (based on 200 patients; lack of information for
staging in 4 patients). †International Union Against Cancer
(UICC) criteria (based on 201 patients; lack of information for
staging in 3 patients). Where the ENETS and UICC criteria are
similar for a given location, a single column is presented.
Otherwise, data for the two classification systems are shown
separately
location by stage according to the UICC classification
and ENETS criteria is presented in Fig. 3. There was
notable discordance with respect to these staging systems
for appendiceal and pancreatic neoplasms.
Discussion
The incidence of GEP-NENobtained from south-western
Norway is among the highest reported in the literature22
and increased significantly over the study interval. The
present population-based study contributes to understand-
ing of the true epidemiology of GEP-NEN. The increas-
ing trend is in line with other studies from the USA
and Europe17,37,38. The high incidence reported in this
study may seem an outlier. However, a previous Swedish
autopsy study26 reported an annual incidence of 8⋅4 NETs
per 100 000 inhabitants (including fewer than 10 per cent
bronchial tumours), which represents a sevenfold increase
from that recorded by the Swedish National Cancer Reg-
ister over the same interval (1958–1969). These find-
ings are also consistent with current understanding of the
epidemiology of NEN, that there is likely to be a sub-
stantial discrepancy between clinically discovered lesions
(those reported to a regional or national registry) and
their true incidence (asymptomatic, non-diagnosed dis-
ease). The autopsy rate was high in the Swedish study26,
with 99 per cent of patients who died in hospital and 63 per
cent in general undergoing autopsy. Current autopsy rates
in most countries are not comparable and make similar
studies difficult39,40.
The observed discrepancy between the present find-
ings together with the Swedish autopsy study26 and the
overall reported incidence of GEP-NEN in the liter-
ature may have several explanations. Approximately 90
per cent of the neuroendrine neoplasms identified in the
Swedish autopsy studywere previously undetected. Clearly,
many patients with NEN are asymptomatic and remain
undiagnosed, and these tumours may therefore be clin-
ically insignificant19,41. However, the clinical presenta-
tion of NETs is often non-specific, and the average delay
from onset of symptoms to diagnosis is suggested to be
between 5 and 7 years42,43. An increased awareness of NEN
among clinicians, radiologists and pathologists, together
with widespread use of improved diagnostic tools (such as
somatostatin receptor imaging, CT, endoscopies and spe-
cific IHC markers), has increased the number of patients
with incidentally discovered NEN44. These tumours may
have gone undetected in the patient’s life-time in the
Swedish cohort. Demographic changes that include an
ageing population might also contribute to this increase,
because the frequency of NEN increases with age22, as also
shown here. Finally, the increased incidence has also been
attributed in part to improved pathological classification; a
greater proportion of previously undifferentiated carcino-
mas are now recognized as NECs37.
A concern related to epidemiological figures from cancer
registries (such as the National Cancer Institute Surveil-
lance, Epidemiology and End Results (SEER) database
and the Cancer Registry of Norway) is that the recording
of NEN is usually restricted to ‘malignant carcinoids’,
thereby disregarding benign tumours and NEN with
uncertain malignant potential, as noted by Hauso and
colleagues45. A rather low, although increasing, annual
incidence of GEP-NEN of 2⋅38 per 100 000 (USA 2000;
for interval 2000–2004), as can be calculated from that
study45, is explained mainly by under-reporting to the
registry.
Data collection over long intervals introduces bias of
disease definitions and classifications22. A lower inci-
dence of GEP-NEN is usually reported from other series.
A French study15 found an annual age-adjusted (world)
incidence rate associated with malignant digestive NEN
(pancreatic lesions included) of 0⋅76 per 100 000 men and
0⋅50 per 100 000 women. The study had a higher median
age and a smaller proportion of appendiceal tumours
than the present investigation. Although an increasing
incidence was observed (1976–1999), differences between
these two studies can be explained mainly by the fact
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that only malignant tumours were included in the French
analysis16. A prospective 1-year audit of GEP-NEN from
Austria13 reported an annual age-adjusted incidence rate
(USA 2000) of 2⋅99 per 100 000 inhabitants. Tumours
were most frequently located in the stomach, whereas the
small bowel was less commonly affected. Although the
authors assumed a high degree of completeness of the data,
one-quarter of the 41 institutions involved did not report
any patients, suggesting possible detection bias. Finally, a
study from the Netherlands Cancer Registry37 reported an
age-standardized (with respect to European standardized
rate) increase in the incidence of NEN from 2⋅1 in 1990 to
4⋅9 per 100 000 inhabitants in 2010. Although this supports
an increasing incidence, the lower reported incidence is
again likely to be explained by a reporting bias towards
malignant disease.
The well defined, controlled sample and the centralized
infrastructure of the healthcare system in the region serves
as an excellent basis for epidemiological research, and is a
strength of the present study. The present data obviously
contrast with publications from tertiary referral centres,
which have an inherent selection bias towards overt malig-
nant and difficult-to-manage cases, which might impede
data interpretation. Patient migration out of the region is
minimal, which limits the influence of regional referral pat-
terns, different treatment policies or patients diagnosed at
other institutions. The most updated definitions and clas-
sifications of GEP-NEN have been used. To ensure appro-
priate comparison of incidence data, commonly used refer-
ence populations22 were employed.
Limitations of this study are the size of the population at
risk, the retrospective design and the accrual period of 11
years. However, the transparent and controlled access to
data in the study region is probably superior to collection
of general data reported to a national registry. The period
of 11 years should also allow fairly comparable diagnostic
opportunities, whereas a longer lag time would potentially
increase the variability in diagnostic approach.
Comparing the present high and increasing incidence
of GEP-NEN in south-western Norway with recently
published data from various regions, it is evident that
appropriate identification and reporting of patients with
NEN remain a challenge.
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